Drug Trial News

RSS

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation, according to a study conducted globally by American and French researchers.

17 May 2011

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at the 2011 International Conference of the American Thoracic Society, being held in Denver May 13-18, 2011.

16 May 2011

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced that results from a clinical study evaluating the safety and efficacy of Caldolor Injection in treating fever and pain in hospitalized burn patients was published in Volume 32, Number 1 of the Journal of Burn Care & Research.

16 May 2011

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Vancouver, British Columbia.

16 May 2011

Synexus completes CT327 phase II psoriasis trial for Creabilis

Synexus has completed a phase II study for the European biotech, Creabilis, recruiting 26 patients in the UK to the psoriasis trial of its CT327 lead product in just 2 weeks, as part of an international proof-of-concept study. The company delivered the targeted number of patients well within the agreed timelines and budget.

From AES - Accelerated Enrollment Solutions 16 May 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France.

16 May 2011

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Preliminary results from a multicountry clinical trial, sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), show that HIV-positive people who take combination antiretroviral therapy (ART) can reduce the risk of transmitting the virus to their HIV-negative partners by 96 percent, U.S. researchers announced on Thursday " in what is being hailed as a breakthrough in HIV prevention," the Los Angeles Times reports.

16 May 2011

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).

16 May 2011

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

\VAYA Pharma announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).

16 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Optimer Pharmaceuticals today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID, an investigational antibiotic for the treatment of Clostridium difficile Infection, at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland.

13 May 2011

Early antiretroviral treatment can halt HIV spread in couples

A research study led by the University of North Carolina at Chapel Hill has made a major discovery in the effort to halt the spread of HIV, the virus that causes AIDS.

13 May 2011

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised $1 million from a new undisclosed investor. The funds will be used to advance its lead program, TTI-1612, into clinical trials for the treatment of interstitial cystitis, also known as bladder pain syndrome. The first trial is projected to start in the second half of this year.

12 May 2011

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented new clinical and pre-clinical data related to the safety and efficacy of its novel, lead defensin-mimetic antibiotic, PMX-30063.

12 May 2011

Drug Trial News

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Synexus completes CT327 phase II psoriasis trial for Creabilis

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Early antiretroviral treatment can halt HIV spread in couples

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News